Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00660673
Registration number
NCT00660673
Ethics application status
Date submitted
15/04/2008
Date registered
17/04/2008
Titles & IDs
Public title
Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease
Query!
Scientific title
Open-Label Continuation Treatment Study With Levodopa - Carbidopa Intestinal Gel In Subjects With Advanced Parkinson's Disease And Severe Motor-Fluctuations Who Have Exhibited A Persistent And Positive Effect To Treatment In Previous Studies
Query!
Secondary ID [1]
0
0
2008-001329-33
Query!
Secondary ID [2]
0
0
S187.3.005
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Advanced Parkinson's Disease
0
0
Query!
Condition category
Condition code
Neurological
0
0
0
0
Query!
Parkinson's disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Levodopa-Carbidopa Intestinal Gel (LCIG)
Treatment: Devices - CADD-Legacy® 1400 ambulatory infusion pump
Treatment: Devices - Percutaneous Endoscopic Gastrostomy with jejunal extension tube (PEG-J)
Experimental: Levodopa-Carbidopa Intestinal Gel - Initial dosing is based on the dosing regimen that the participant received during the previous LCIG study. Dosing is individually optimized and can be adjusted at any time during the study as clinically indicated. The total dose/day of LCIG is composed of 3 individually adjusted doses. The morning dose is administered as a bolus infusion, usually 5 to 10 mL (100 to 200 mg levodopa). The maintenance dose is adjustable in steps of 2 mg/hour (0.1 mL/hour), within a range of 1 to 10 mL/hour (20 to 200 mg levodopa/hour) and is usually 2 to 6 mL/hour (40 to 120 mg levodopa/hour). Participants will be allowed to self-administer extra doses of LCIG to address immediate medical needs, normally 0.5 to 2.0 mL.
Participants will receive LCIG until it is commercially available.
Treatment: Drugs: Levodopa-Carbidopa Intestinal Gel (LCIG)
LCIG for upper-intestinal infusion is a suspension of levodopa (20 mg/mL) and carbidopa (5 mg/mL) in an aqueous gel that is dispensed in a medication cassette reservoir containing 100 mL of LCIG.
Treatment: Devices: CADD-Legacy® 1400 ambulatory infusion pump
Portable infusion pump (CADD-Legacy Pump Model 1400) connected to the LCIG medication cassette reservoir.
Treatment: Devices: Percutaneous Endoscopic Gastrostomy with jejunal extension tube (PEG-J)
All participants previously had a PEG-J placed in one of the prior LCIG studies.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Intervention code [2]
0
0
Treatment: Devices
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Participants With Treatment-emergent Adverse Events
Query!
Assessment method [1]
0
0
Treatment-emergent adverse events (TEAEs) are defined as adverse events (AEs) which started on or after the date of the first LCIG Infusion in this study and within 30 days of the date of the last PEG-J exposure.
At least possibly drug-related is defined as TEAEs assessed as having a "Possible" or "Probable" or missing relationship to study drug.
Serious AEs included any untoward medical occurrence that:
* Resulted in death
* Was life-threatening
* Required inpatient hospitalization or prolongation of an existing hospitalization
* Resulted in persistent or significant disability/incapacity
* was a congenital anomaly/birth defect
The severity of all AEs was characterized as mild, moderate or severe according to the following definitions:
* Mild: usually transient and do not interfere with daily activities.
* Moderate: low level of inconvenience or concern to the subject, may interfere with daily activities.
* Severe: events interrupt the subject's usual daily activity.
Query!
Timepoint [1]
0
0
From first dose of LCIG in this study up to 30 days after the date of last PEG-J exposure; median duration of treatment was 1178 days, with a maximum of 4217 days (11.5 years).
Query!
Secondary outcome [1]
0
0
Number of Participants With Device Complications
Query!
Assessment method [1]
0
0
Device complications include complications with the pump, intestinal tube, PEG-J or stoma.
Query!
Timepoint [1]
0
0
From first dose of LCIG in this study up to 30 days after the date of last PEG-J exposure; median duration of treatment was 1178 days.
Query!
Secondary outcome [2]
0
0
Number of Participants With Sleep Attacks
Query!
Assessment method [2]
0
0
Participants were asked whether they experienced any events in which they fell asleep suddenly or unexpectedly, including while engaged in some activity (e.g., eating/drinking, speaking, or driving) or at rest, with or without any previous warning of sleepiness. If yes, participants were asked if they suffered any "bad" outcome or problem from the falling asleep event.
Query!
Timepoint [2]
0
0
Baseline (final assessment period of the previous open-label LCIG study) and every 6 months until final visit; median duration of treatment was 1178 days.
Query!
Secondary outcome [3]
0
0
Number of Participants With Intense Impulsive Behavior
Query!
Assessment method [3]
0
0
To monitor for the development of intense impulsive behavior the Minnesota Impulsive Disorder Interview (MIDI) was administered. The MIDI is a semi-structured clinical interview assessing pathological gambling, trichotillomania, kleptomania, pyromania, intermittent explosive disorder, compulsive buying, and compulsive sexual behavior.
Query!
Timepoint [3]
0
0
Baseline (final assessment of the previous open-label LCIG study) and every 6 months until final visit; median duration of treatment was 1178 days.
Query!
Secondary outcome [4]
0
0
Number of Participants Who Developed Melanoma
Query!
Assessment method [4]
0
0
A comprehensive assessment for the presence of melanoma was performed at least once a year by a dermatologist.
Query!
Timepoint [4]
0
0
Once per year during the study; median duration of treatment was 1178 days.
Query!
Secondary outcome [5]
0
0
Number of Participants With Treatment-emergent Adverse Events of Special Interest (TE AESI)
Query!
Assessment method [5]
0
0
Adverse events of special interest (AESIs) were identified using standardized Medical Dictionary for Regulatory Activities (MedDRA) queries (SMQ) or company MedDRA queries (CMQs). The AESI in the following categories were identified on the basis of review of the clinical program and postmarketing observations where the treatment system is commercially available.
* Procedure and device associated events
* Polyneuropathy, included preferred terms in either the peripheral neuropathy or GuillainBarre syndrome standardized MedDRA query (narrow search), such as polyneuropathy, decreased vibratory sense, peripheral neuropathy, peripheral sensory neuropathy, neuralgia, demyelinating polyneuropathy, and sensory disturbance
* Weight loss
* Cardiovascular fatalities
* Respiratory tract aspiration including aspiration pneumonia/pneumonitis.
Query!
Timepoint [5]
0
0
From first dose of LCIG in this study up to 30 days after the date of last PEG-J exposure; median duration of treatment was 1178 days, with a maximum of 4217 days (11.5 years).
Query!
Secondary outcome [6]
0
0
Number of Participants With Any Suicidal Ideation or Behavior
Query!
Assessment method [6]
0
0
The Columbia-Suicide Severity Rating Scale (C-SSRS) was implemented with Protocol Amendment 3 (20 March 2012) in order to assess suicidal behavior and ideation.
Suicidal ideation includes the wish to be dead, nonspecific active suicidal thoughts, active ideation without intent to act, active ideation with some intent to act, and active ideation with specific plan or intent. Suicidal behavior includes actual attempts, interrupted attempts, aborted attempts, completed suicide, and preparatory acts or behaviors.
The number of participants with affirmative responses on the C-SSRS at any time during the treatment period is reported.
Query!
Timepoint [6]
0
0
Every 6 months (beginning with implementation of Protocol Amendment 3) until final visit; median duration of treatment was 1178 days.
Query!
Secondary outcome [7]
0
0
Number of Participants With Potentially Clinically Significant Vital Sign Values
Query!
Assessment method [7]
0
0
A vital sign value was considered potentially clinically significant if it satisfied the pre-specified criteria presented in the table and was also more extreme than the participant's corresponding Baseline value.
Query!
Timepoint [7]
0
0
Baseline and every 6 months until final visit; median duration of treatment was 1178 days.
Query!
Secondary outcome [8]
0
0
Number of Participants With Potentially Clinically Significant Hematology Laboratory Values
Query!
Assessment method [8]
0
0
A laboratory value was considered potentially clinically significant if it satisfied the pre-specified criteria presented in the table and was also more extreme than the participant's corresponding Baseline value.
Query!
Timepoint [8]
0
0
Baseline and every 6 months until final visit; median duration of treatment was 1178 days.
Query!
Secondary outcome [9]
0
0
Number of Participants With Potentially Clinically Significant Chemistry Laboratory Values
Query!
Assessment method [9]
0
0
A laboratory value was considered potentially clinically significant if it satisfied the pre-specified criteria presented in the table and was also more extreme than the participant's corresponding baseline value.
ULN = upper limit of normal
Query!
Timepoint [9]
0
0
Baseline and every 6 months until final visit; median duration of treatment was 1178 days.
Query!
Secondary outcome [10]
0
0
Number of Participants With Vitamin Levels Outside of the Normal Range
Query!
Assessment method [10]
0
0
Special tests for vitamin deficiencies (folic acid, vitamin B6, vitamin B12, methylmalonic acid \[MMA\], and homocysteine) were implemented with Protocol Amendment 2 (27 July 2011). The number of participants with vitamin levels outside of the normal range at any time post-baseline is reported for each vitamin tested.
Query!
Timepoint [10]
0
0
Every 6 months (beginning with implementation of Protocol Amendment 2) until final visit; median duration of treatment was 1178 days.
Query!
Secondary outcome [11]
0
0
Number of Participants Receiving Concomitant Anti-Parkinson's Disease Medications by Treatment Year
Query!
Assessment method [11]
0
0
Participants could use oral levodopa-carbidopa for scheduled or supplemental bedtime/overnight doses after the pump was disconnected for the night, or as rescue medication in case of acute deterioration caused by failure of the LCIG system such as tubes and/or the pump or the onset of an acute illness.
The initiation of additional concomitant PD medication was allowed at the discretion of the Investigator if medically indicated.
Query!
Timepoint [11]
0
0
Year 1, Year 2, Year 3, Year 4, Year 5, Year 6, Year 7, Year 8, Year 9, Year 10, > Year 10 (maximum time on treatment was approximately 11.5 years).
Query!
Secondary outcome [12]
0
0
Change in Average Daily "Off" Time Based on the Parkinson's Disease Symptom Diary at End of Treatment
Query!
Assessment method [12]
0
0
The PD symptom diary asks participants (or their caregivers) to indicate their status upon waking and every 30 minutes during their normal waking time according to the following categories: asleep, "off", "on" without dyskinesia, "on" with non-troublesome dyskinesia, or "on" with troublesome dyskinesia.
"Off" time was defined as time when medication had worn off and was no longer providing benefit with regard to mobility, slowness, and stiffness.
PD diary times were normalized to a 16-hour waking day and averaged for the 3 days prior to each study visit.
A negative change for "off" time indicates improvement. The PD diary assessment was implemented with Protocol amendment 4 (December 2013) for participants at United States (US) sites only.
Query!
Timepoint [12]
0
0
Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Query!
Secondary outcome [13]
0
0
Change in Average Daily "On" Time Without Troublesome Dyskinesia Based on the Parkinson's Disease Symptom Diary at End of Treatment
Query!
Assessment method [13]
0
0
The PD diary asks participants (or their caregivers) to indicate their status upon waking and every 30 minutes during their normal waking time according to the following categories: asleep, "off", "on" without dyskinesia, "on" with non-troublesome dyskinesia, or "on" with troublesome dyskinesia.
"On" time is when medication is providing benefit with regard to mobility, slowness and stiffness. Dyskinesia is involuntary twisting, turning movements which are an effect of medication and occur during "on" time. Non-troublesome dyskinesia does not interfere with function or cause meaningful discomfort.
"On" time without troublesome dyskinesia is the sum of "on" time without dyskinesia and "on" time with non-troublesome dyskinesia. PD diary times were normalized to a 16-hour waking day and averaged for the 3 days prior to each study visit. A positive change indicates improvement.
The PD diary was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.
Query!
Timepoint [13]
0
0
Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Query!
Secondary outcome [14]
0
0
Change in Average Daily "On" Time With Troublesome Dyskinesia Based on the Parkinson's Disease Symptom Diary at End of Treatment
Query!
Assessment method [14]
0
0
The PD diary asks participants (or their caregivers) to indicate their status upon waking and every 30 minutes during their normal waking time according to the following categories: asleep, "off", "on" without dyskinesia, "on" with non-troublesome dyskinesia, or "on" with troublesome dyskinesia.
"On" time is when medication is providing benefit with regard to mobility, slowness and stiffness. Dyskinesia is involuntary twisting, turning movements which are an effect of medication and occur during "on" time. Troublesome dyskinesia interferes with function or causes meaningful discomfort.
PD diary times were normalized to a 16-hour waking day and averaged for the 3 days prior to each study visit. A positive change indicates improvement.
The PD diary was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.
Query!
Timepoint [14]
0
0
Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Query!
Secondary outcome [15]
0
0
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part I Score at End of Treatment
Query!
Assessment method [15]
0
0
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections:
I) Mentation, Behavior, and Mood;
II) Activities of Daily Living;
III) Motor Examinations;
IV) Complications of Therapy sections (including dyskinesias).
The Part I Score is the sum of the answers to the 4 questions that comprise Part I, each of which are measured on a 5-point scale (0-4). The Part I score ranges from 0-16 and higher scores are associated with more disability. A negative change from Baseline indicates improvement.
The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.
Query!
Timepoint [15]
0
0
Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Query!
Secondary outcome [16]
0
0
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score at End of Treatment
Query!
Assessment method [16]
0
0
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections:
I) Mentation, Behavior, and Mood;
II) Activities of Daily Living;
III) Motor Examinations;
IV) Complications of Therapy sections (including dyskinesias).
The Part II score is the sum of the answers to the 13 questions that comprise Part II, each of which are measured on a 5-point scale (0-4). The Part II score ranges from 0-52 and higher scores are associated with more disability. A negative change from Baseline indicates improvement.
The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.
Query!
Timepoint [16]
0
0
Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Query!
Secondary outcome [17]
0
0
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score at End of Treatment
Query!
Assessment method [17]
0
0
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections:
I) Mentation, Behavior, and Mood;
II) Activities of Daily Living;
III) Motor Examinations;
IV) Complications of Therapy sections (including dyskinesias).
UPDRS Part III consists of 14 questions. Questions 20 - 26 are multi-part questions in that they are evaluated separately for multiple body parts. Counting each of these assessments leads to a total of 27 answers for Part III. The UPDRS Part III score is the sum of the 27 answers provided to the 14 Part III questions, each of which are measured on a 5-Point scale (0-4). The Part III score ranges from 0-108 and higher scores are associated with more disability. A negative change from Baseline indicates improvement.
The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.
Query!
Timepoint [17]
0
0
Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Query!
Secondary outcome [18]
0
0
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Total Score at End of Treatment
Query!
Assessment method [18]
0
0
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections:
I) Mentation, Behavior, and Mood;
II) Activities of Daily Living;
III) Motor Examinations;
IV) Complications of Therapy sections (including dyskinesias).
The UPDRS total score is the sum of the responses to the 31 questions (44 answers) that comprise Parts I - III of the scale. The total score ranges from 0 - 176 with 176 representing the worst (total) disability, and 0 no disability. A negative change from Baseline indicates improvement.
The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.
Query!
Timepoint [18]
0
0
Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Query!
Secondary outcome [19]
0
0
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Score at End of Treatment
Query!
Assessment method [19]
0
0
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections:
I) Mentation, Behavior, and Mood;
II) Activities of Daily Living;
III) Motor Examinations;
IV) Complications of Therapy sections (including Dyskinesias).
The UPDRS Part IV Score is the sum of all answers to the 11 questions that comprise Part IV, 4 of which are measured on a 5-point scale (0 - 4) and 7 which are measured on a 2-point scale (0 - 1). The Part IV score ranges from 0 - 23 with higher scores associated with more disability. A negative change from Baseline indicates improvement.
The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.
Query!
Timepoint [19]
0
0
Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Query!
Secondary outcome [20]
0
0
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Dyskinesia Score at End of Treatment
Query!
Assessment method [20]
0
0
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of PD. It is made up of the following sections:
I) Mentation, Behavior, and Mood; II) Activities of Daily Living; III) Motor Examinations; IV) Complications of Therapy sections (including Dyskinesias); and
The UPDRS Part IV dyskinesia Score is the sum of Questions 32 (What proportion of the waking day are dyskinesias present?), 33 (How disabling are the dyskinesias? ), and 34 (How painful are the dyskinesias?) on UPDRS Part IV, each of which are measured on a 5-point scale (0-4). The Part IV dyskinesia score ranges from 0 - 12 and higher scores are associated with more disability. A negative change from Baseline indicates improvement.
The UPDRS was implemented with Protocol amendment 4 (December 2013) for participants at US sites only.
Query!
Timepoint [20]
0
0
Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Query!
Secondary outcome [21]
0
0
Change in Parkinson's Disease Questionnaire (PDQ-39) Scores at End of Treatment
Query!
Assessment method [21]
0
0
The PDQ-39 is a self-administered questionnaire that comprises 39 items addressing the following eight domains of health that patients consider to be adversely affected by the disease:
* Mobility (e.g., fear of falling when walking) - 10 questions
* Activities of daily living (e.g., difficulty cutting food) - 6 questions
* Emotional well-being (e.g., feelings of isolation) - 6 questions
* Stigma (e.g., social embarrassment) - 4 questions
* Social support - 3 questions
* Cognition - 4 questions
* Communication - 3 questions
* Bodily discomfort - 3 questions
Each question is answered on a 5-point scale from 0 (Never) to 4 (Always / Cannot Do At All). Scores are calculated by summing the answers to the questions in the domain and converting to a scale from 0 to 100. Higher scores are associated with the more severe symptoms of the disease such as tremor and stiffness. The PDQ-39 summary index (range 0-100) includes responses to all 39 items. A negative change indicates improvement.
Query!
Timepoint [21]
0
0
Prior to initial LCIG infusion (in the previous study, before the first LCIG infusion), Baseline (final assessment of the previous open-label LCIG study), and end of treatment; median duration of treatment was 1178 days.
Query!
Eligibility
Key inclusion criteria
* The participant should have completed participation in Study S187.3.003 or S187.3.004; and, in the opinion of the Principal Investigator, would benefit from long-term treatment with LCIG.
* For Canada, participants will be allowed to participate in the S187.3.005 study with a minimum of 6 months of exposure to LCIG in the S187.3.004 study.
* The participant must be able to understand the nature of the study and must provide written informed consent prior to the conduct of any study related procedures. If the participant does not have the capacity to provide informed consent, full informed consent must be obtained from the participant's legally authorized representative. Consenting will be performed according to local regulations.
Query!
Minimum age
30
Years
Query!
Query!
Maximum age
99
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Medical, laboratory, psychiatric, or surgical issues deemed by the investigator to be clinically significant and which could interfere with the participant's participation in the study.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
NA
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
13/11/2009
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
30/11/2021
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
262
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Query!
Recruitment hospital [1]
0
0
Westmead Hospital /ID# 50081 - Westmead
Query!
Recruitment hospital [2]
0
0
Royal Adelaide Hospital /ID# 50083 - Adelaide
Query!
Recruitment hospital [3]
0
0
Austin Hospital /ID# 50082 - Heidelberg
Query!
Recruitment postcode(s) [1]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [2]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [3]
0
0
3084 - Heidelberg
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
District of Columbia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Georgia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Illinois
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Kentucky
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Louisiana
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Maryland
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Missouri
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Nebraska
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
New York
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
North Carolina
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Ohio
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Vermont
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Washington
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Wisconsin
Query!
Country [19]
0
0
Canada
Query!
State/province [19]
0
0
Alberta
Query!
Country [20]
0
0
Canada
Query!
State/province [20]
0
0
Ontario
Query!
Country [21]
0
0
Canada
Query!
State/province [21]
0
0
Quebec
Query!
Country [22]
0
0
Czechia
Query!
State/province [22]
0
0
Brno
Query!
Country [23]
0
0
Czechia
Query!
State/province [23]
0
0
Hradec Králové
Query!
Country [24]
0
0
Czechia
Query!
State/province [24]
0
0
Pardubice
Query!
Country [25]
0
0
Czechia
Query!
State/province [25]
0
0
Praha
Query!
Country [26]
0
0
Israel
Query!
State/province [26]
0
0
Tel-Aviv
Query!
Country [27]
0
0
New Zealand
Query!
State/province [27]
0
0
Waikato
Query!
Country [28]
0
0
New Zealand
Query!
State/province [28]
0
0
Auckland
Query!
Country [29]
0
0
New Zealand
Query!
State/province [29]
0
0
Christchurch
Query!
Country [30]
0
0
New Zealand
Query!
State/province [30]
0
0
Wellington
Query!
Country [31]
0
0
Poland
Query!
State/province [31]
0
0
Lodzkie
Query!
Country [32]
0
0
Poland
Query!
State/province [32]
0
0
Wielkopolskie
Query!
Country [33]
0
0
Portugal
Query!
State/province [33]
0
0
Coimbra
Query!
Country [34]
0
0
Portugal
Query!
State/province [34]
0
0
Lisboa
Query!
Country [35]
0
0
Portugal
Query!
State/province [35]
0
0
Porto
Query!
Country [36]
0
0
Russian Federation
Query!
State/province [36]
0
0
Kazan
Query!
Country [37]
0
0
Russian Federation
Query!
State/province [37]
0
0
Moscow
Query!
Country [38]
0
0
Russian Federation
Query!
State/province [38]
0
0
Saint Petersburg
Query!
Country [39]
0
0
Thailand
Query!
State/province [39]
0
0
Bangkok
Query!
Country [40]
0
0
United Kingdom
Query!
State/province [40]
0
0
Liverpool
Query!
Country [41]
0
0
United Kingdom
Query!
State/province [41]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
AbbVie
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Other
Query!
Name [1]
0
0
IQVIA, formerly Quintiles
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The primary objective of this study is to provide continued access to levodopa-carbidopa intestinal gel (LCIG), to participants who have already participated in an open-label efficacy and safety study with the same treatment (Study S187.3.003 \[NCT00360568\] or Study S187.3.004 \[NCT00335153\]).
Query!
Trial website
https://clinicaltrials.gov/study/NCT00660673
Query!
Trial related presentations / publications
Fernandez HH, Boyd JT, Fung VSC, Lew MF, Rodriguez RL, Slevin JT, Standaert DG, Zadikoff C, Vanagunas AD, Chatamra K, Eaton S, Facheris MF, Hall C, Robieson WZ, Benesh J, Espay AJ. Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's disease. Mov Disord. 2018 Jul;33(6):928-936. doi: 10.1002/mds.27338. Epub 2018 Mar 23.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
ABBVIE INC.
Query!
Address
0
0
AbbVie
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Clinical study report (CSR)
Query!
When will data be available (start and end dates)?
For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Query!
Available to whom?
Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
IPD available at link: https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/73/NCT00660673/Prot_000.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/73/NCT00660673/SAP_001.pdf
Results publications and other study-related documents
Type
Citations or Other Details
Journal
Fernandez HH, Boyd JT, Fung VSC, Lew MF, Rodriguez...
[
More Details
]
Results are available at
https://clinicaltrials.gov/study/NCT00660673